The Journal of Immunology, Vol 151, Issue 5 2538-2545, Copyright © 1993 by American Association of Immunologists

ARTICLES

Presentation of the Mls-1 superantigen by human HLA class II molecules to murine T cells

M Subramanyam, B McLellan, N Labrecque, RP Sekaly and BT Huber
Department of Pathology, Tufts University School of Medicine, Boston, MA 02111.

Superantigens (SAG) presented in the context of MHC class II proteins stimulate a strong proliferative response in T cells expressing particular TCR V beta genes. Although this T-cell recognition is not MHC restricted, a strong hierarchy is observed in the ability of various MHC class II molecules to present SAG. Mls-1, encoded by the Murine Mammary Tumor Virus (MMTV) Mtv-7 sag gene, is the prototype of endogenous SAG. In the present study, we have analyzed whether this retroviral gene product can be presented in the context of human HLA class II proteins to murine T cells. Positive results were obtained with the DR isotype and in in vitro, as well as in vivo T-cell stimulation assays. However, the various DR beta alleles, expressed in combination with an identical DR alpha chain, differed in their Mls-1 presenting capacity, indicating that the MHC class II beta-chain contains the primary contact site for Mls-1. Interestingly, the same pattern of TCR V beta restriction was seen in response to Mls-1 presented in the context of human and mouse class II, suggesting that the TCR V beta specificity is uniquely determined by the retroviral SAG. Furthermore, Mls-1 presented in the context of the DQw1 and DPw2 isotypes did not elicit a T-cell response. The results from this study form the basis for further analysis of the exact region in the class II beta-chain that interacts with Mls-1.

This article has been cited by other articles:

				G. Cabrera, D. Burzyn, J. Mundinano, M. C. Courreges, G. Camicia, D. Lorenzo, H. Costa, S. R. Ross, I. Nepomnaschy, and I. Piazzon Early Increases in Superantigen-Specific Foxp3+ Regulatory T Cells during Mouse Mammary Tumor Virus Infection J. Virol., August 1, 2008; 82(15): 7422 - 7431. [Abstract] [Full Text] [PDF]

				G. A. Azar, R.-P. Sekaly, and J. Thibodeau A Defective Viral Superantigen-Presenting Phenotype in HLA-DR Transfectants Is Corrected by CIITA J. Immunol., June 15, 2005; 174(12): 7548 - 7557. [Abstract] [Full Text] [PDF]

				T. T. Duong, E. D. Silverman, M. V. Bissessar, and R. S. M. Yeung Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease Int. Immunol., January 1, 2003; 15(1): 79 - 89. [Abstract] [Full Text] [PDF]

				P.-N. Hsu, P. W. Bryant, N. Sutkowski, B. McLellan, H. L. Ploegh, and B. T. Huber Association of Mouse Mammary Tumor Virus Superantigen with MHC Class II During Biosynthesis J. Immunol., March 1, 2001; 166(5): 3309 - 3314. [Abstract] [Full Text] [PDF]

				M. Lapatschek, S. Dürr, R. Löwer, C. Magin, H. Wagner, and T. Miethke Functional Analysis of the env Open Reading Frame in Human Endogenous Retrovirus IDDMK1,222 Encoding Superantigen Activity J. Virol., July 15, 2000; 74(14): 6386 - 6393. [Abstract] [Full Text]

				P. Luppi, W. A. Rudert, M. M. Zanone, G. Stassi, G. Trucco, D. Finegold, G. J. Boyle, P. D. Nido, F. X. McGowan Jr, and M. Trucco Idiopathic Dilated Cardiomyopathy : A Superantigen-Driven Autoimmune Disease Circulation, August 25, 1998; 98(8): 777 - 785. [Abstract] [Full Text] [PDF]

				M. Delcourt, J. Thibodeau, F. Denis, and R.-P. Sekaly Paracrine Transfer of Mouse Mammary Tumor Virus Superantigen J. Exp. Med., February 3, 1997; 185(3): 471 - 480. [Abstract] [Full Text] [PDF]